Hospital
ST Francis Medical Center, INC
ST Francis Medical Center, INC was paid $27.12M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoST FRANCIS MEDICAL CENTER, INC
MONROE, LA 71201
MONROE, LA 71201
33aNPI1295723229assigned 10/13/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.12M
24GClaims928,863
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#17 of 96
Median peer was paid$5.17M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,541 | $2.46M | |
| 2019 | 120,909 | $3.40M | |
| 2020 | 98,657 | $2.81M | |
| 2021 | 131,207 | $4.53M | |
| 2022 | 150,963 | $4.74M | |
| 2023 | 181,058 | $5.18M | |
| 2024incomplete | 140,528 | $4.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 63,798 | 58,271 | $5.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 33,203 | 29,929 | $3.56M |
| 41899 | Unlisted procedure, dentoalveolar structures | 7.0% | 3,347 | 2,999 | $1.91M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 13,943 | 12,254 | $1.78M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.4% | 3,823 | 3,414 | $1.47M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 22,838 | 21,386 | $1.39M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 8,248 | 7,376 | $998K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.4% | 10,165 | 9,040 | $920K |
| 71045 | Radiologic examination, chest; single view | 3.3% | 34,405 | 30,660 | $889K |
| 80053 | Comprehensive metabolic panel | 2.2% | 86,562 | 75,185 | $590K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.0% | 1,564 | 1,445 | $550K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 2,043 | 1,818 | $525K |
172 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 36,075 | $468K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 10,414 | $450K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.6% | 876 | $447K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 29,833 | $386K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 18,390 | $384K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 77,772 | $381K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 1.2% | 1,316 | $317K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 18,554 | $311K |
| 83880 | 1.1% | 16,815 | $307K | |
| 59025 | Fetal non-stress test | <1% | 4,388 | $251K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,075 | $220K |
| 84484 | <1% | 30,154 | $188K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 91,942 | $159K |
| 93458 | <1% | 185 | $143K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,529 | $130K |
| 80050 | General health panel | <1% | 2,911 | $117K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,184 | $114K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 258 | $112K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,665 | $107K |
| 87581 | <1% | 3,514 | $100K | |
| 87486 | <1% | 3,520 | $100K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,246 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,064 | $86K |
| 81001 | <1% | 45,363 | $84K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 349 | $83K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,787 | $82K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 554 | $76K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,471 | $68K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,269 | $63K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 264 | $61K |
| 83690 | <1% | 11,772 | $55K | |
| 80061 | Lipid panel | <1% | 4,577 | $54K |
| 82077 | <1% | 6,140 | $53K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,793 | $51K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,003 | $41K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,005 | $41K |
| 82550 | <1% | 10,817 | $35K | |
| 85730 | <1% | 12,684 | $34K | |
| 83605 | <1% | 5,993 | $34K | |
| 87040 | <1% | 5,824 | $32K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 505 | $31K |
| 85610 | <1% | 15,189 | $31K | |
| 84703 | <1% | 4,808 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 635 | $29K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 700 | $27K |
| 85027 | <1% | 5,520 | $27K | |
| 83735 | <1% | 7,794 | $27K | |
| 74022 | <1% | 595 | $26K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 973 | $25K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 73 | $24K |
| 87081 | <1% | 3,833 | $24K | |
| 82553 | <1% | 4,538 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,538 | $18K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 73 | $18K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 480 | $16K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 93 | $16K |
| 81025 | <1% | 2,426 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 938 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,665 | $15K |
| 76801 | <1% | 212 | $13K | |
| G0378 | Hospital observation service, per hour | <1% | 52 | $12K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 469 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,088 | $10K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 213 | $10K |
| 80143 | <1% | 853 | $9K | |
| 80179 | <1% | 784 | $9K | |
| 95951 | <1% | 26 | $8K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 28 | $8K |
| C1769 | Guide wire | <1% | 734 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 331 | $8K |
| 82607 | <1% | 520 | $7K | |
| 80074 | <1% | 141 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 462 | $7K |
| 84702 | <1% | 525 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 31 | $7K |
| 82785 | <1% | 387 | $6K | |
| 36600 | <1% | 668 | $6K | |
| 96376 | <1% | 541 | $6K | |
| 84439 | <1% | 579 | $6K | |
| 82805 | <1% | 1,177 | $5K | |
| 80177 | <1% | 399 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $5K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 19 | $4K |
| 95713 | <1% | 27 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 155 | $4K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 826 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,447 | $4K |
| 82043 | <1% | 642 | $4K | |
| 86850 | <1% | 1,246 | $4K | |
| 64483 | <1% | 46 | $3K | |
| 84100 | <1% | 1,674 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,088 | $3K |
| 82570 | <1% | 666 | $3K | |
| 82375 | <1% | 552 | $3K | |
| 86140 | <1% | 828 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 520 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 320 | $3K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 40 | $2K |
| 80183 | <1% | 179 | $2K | |
| 86900 | <1% | 1,601 | $2K | |
| 73630 | <1% | 109 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,986 | $2K |
| 86901 | <1% | 1,588 | $2K | |
| 76000 | <1% | 159 | $2K | |
| 86003 | <1% | 47 | $2K | |
| 87070 | <1% | 232 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,190 | $2K |
| 83050 | <1% | 542 | $2K | |
| 87807 | <1% | 131 | $2K | |
| 86696 | <1% | 72 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 30 | $2K |
| 93017 | <1% | 12 | $1K | |
| 82150 | <1% | 380 | $1K | |
| 87186 | <1% | 193 | $1K | |
| 84145 | <1% | 98 | $1K | |
| 80164 | <1% | 100 | $1K | |
| 85379 | <1% | 198 | $1K | |
| 86694 | <1% | 73 | $1K | |
| 72100 | <1% | 27 | $1K | |
| 86695 | <1% | 72 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 92 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 241 | $940.08 |
| 74018 | <1% | 32 | $889.11 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,267 | $873.19 |
| 86780 | <1% | 56 | $818.60 | |
| 83615 | <1% | 796 | $734.57 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $726.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,540 | $725.62 |
| 85045 | <1% | 164 | $701.12 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,588 | $664.04 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 53 | $649.33 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 111 | $614.14 |
| 81003 | <1% | 312 | $602.96 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 715 | $583.99 |
| 82728 | <1% | 74 | $534.26 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 630 | $491.67 |
| 74019 | <1% | 15 | $485.43 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,960 | $473.55 |
| 73562 | <1% | 17 | $370.17 | |
| 82962 | <1% | 238 | $366.29 | |
| 86592 | <1% | 72 | $337.39 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 20 | $319.09 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 67 | $318.56 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 16 | $284.03 |
| 72170 | <1% | 15 | $260.89 | |
| 85652 | <1% | 97 | $231.97 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 122 | $202.28 |
| 85018 | <1% | 1,142 | $198.34 | |
| 82746 | <1% | 16 | $191.94 | |
| 87077 | <1% | 12 | $145.74 | |
| 84550 | <1% | 30 | $135.38 | |
| 87205 | <1% | 25 | $118.32 | |
| 85651 | <1% | 27 | $98.64 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 381 | $89.03 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $46.43 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 12 | $31.74 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 25 | $18.73 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 17 | $14.51 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $5.91 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 20 | $4.02 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,145 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 1,281 | $0.00 |
| 02414 | 0% | 180 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 90 | $0.00 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 30 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 53 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 672 | $0.00 |
| A9270 | Non-covered item or service | 0% | 257 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 21 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 21 | $0.00 |
| 97010 | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOGAN, RONALD (SR VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| ST Francis Medical Group LLC | Monroe, LA | $8.45M |
| ST Francis Medical Center, INC | Monroe, LA | $727K |
| ST. Francis School Based Health | Monroe, LA | $14K |
| SFMC Hospitalist | Monroe, LA | $2K |
| ST Francis Medical Center, INC | Monroe, LA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.